The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
May. 10, 2022
Filed:
Aug. 07, 2017
Applicant:
Acetylon Pharmaceuticals Inc., Boston, MA (US);
Inventors:
Simon Steward Jones, Harvard, MA (US);
Chengyin Min, Brookline, MA (US);
Steven Norman Quayle, Brookline, MA (US);
Assignee:
Acetylon Pharmaceuticals Inc., Boston, MA (US);
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/505 (2006.01); A61K 45/06 (2006.01); A61K 39/395 (2006.01); A61P 35/00 (2006.01); A61K 9/00 (2006.01); C07K 16/28 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 31/505 (2013.01); A61K 9/0019 (2013.01); A61K 9/0053 (2013.01); A61K 39/3955 (2013.01); A61K 39/39558 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01); C07K 16/2887 (2013.01); A61K 2039/505 (2013.01); A61K 2039/54 (2013.01); C07K 2317/24 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/76 (2013.01);
Abstract
The disclosure relates to pharmaceutical combinations comprising an HDAC6 selective inhibitor and a CD20 inhibitory antibody for the treatment of a B-cell disorder, such as cancer, in a subject in need thereof. Also provided herein are methods for treating a B-cell disorder in a subject in need thereof, comprising administering to the subject an effective amount of an HDAC6 selective inhibitor and a CD20 inhibitory antibody.